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Abstract
Several genetic polymorphisms in immune response genes have been associated to lep-
rosy. This fact converges on the main hypothesis that genetic factors are involved in the 
disease susceptibility in two distinct steps: leprosy per se and their clinical forms. These 
genes play an important role in the recognition process, in the activation of the main meta-
bolic pathway of the immune response and in the evolution of the disease. The scope of this 
project was to highlight the role of the immune response genes in the context of leprosy, 
emphasizing the participation of some of them in the signaling and targeting processes in 
response to bacillus infection and on disease evolution, such as HLA, KIR and MIC genes. 
Some environmental and genetic factors are important when the exposure to the bacillus 
occurs, leading to cure or not. Factors that favor a cellular or humoral immune response 
may influence the clinical manifestations after the infection inducting to one of extreme 
poles. Furthermore, some genetic factors were associated to the type of reaction that some 
individuals present during the disease development. Thus, it is very important to high-
light the participation of some genetic factors in the immunopathogenesis of leprosy.
Keywords: leprosy, HLA genes, MICA genes, KIR genes, genetic predisposition, genetic 
polymorphism
1. Introduction
Leprosy is a chronic infectious granulomatous disease caused by the obligate intracellular 
bacillus Mycobacterium leprae (M. Leprae). Dermatoneurological signs and symptoms, such as 
skin and peripheral nerve lesions, are common manifestations of the disease and occasionally, 
it may affect respiratory tract, eyes, lymph nodes, nasal structures, testicles and internal organs 
[1, 2].
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Leprosy is an important endemic disease, considered as a serious public health and social 
problem worldwide, as it leads to neural impairment or physical disability. Thus, special 
attention is needed, due to the consequences in the socioeconomic life of the patients or even 
their possible sequels in those who are cured. Worldwide, leprosy cases spread across more 
than 140 countries, with 22 countries accounting for 95% of global leprosy. These countries 
such as India, Brazil, Indonesia, Democratic Republic of Congo, Ethiopia, Nepal, Bangladesh 
and others have a high detection rate [3].
Bacillus has a high infectivity and low pathogenicity, that is, it infects many people, but only 
few become ill [1]. Leprosy is influenced by host genetic and mycobacterial factors, and envi-
ronmental factors such as nutritional status and rate of exposure to bacillus. The immune 
response is of fundamental importance for the body’s defense against exposure to the bacil-
lus, but in some individuals, leprosy can lead to changes in the immune response and to the 
development of distinct clinical forms. Among those who fall ill, the degree of immunity var-
ies by determining the clinical form and course of the disease [4].
The immune response to the M. leprae is a task of the T lymphocytes responsible for adaptive 
immunity. CD4+ T lymphocytes can be divided into two subpopulations, which exert differ-
ent functions in the defense of the organism mainly against intracellular bacterial infections, 
such as leprosy. These lymphocytes have the ability to induce the cellular or humoral immune 
response that is related to the types of secreted cytokines and the development of Th1 or Th2 
responses [5, 6].
The predominance of cellular or humoral immune response may influence the evolution of 
the leprosy and the clinical characteristics observed in the tuberculoid (TT) and lepromatous 
(LL) clinical forms. The patients with the TT form have a strong cellular immune response, 
with a predominance of Th1 cells, activation of macrophages and Th1 cytokines secretion, 
such as interleukin (IL)-2, IL-6, IL-12, IL-15, IL-18, tumor necrosis factor-alpha (TNF-α) 
and interferon-gamma (IFN-γ), limiting the disease to few localized lesions of the skin and 
peripheral nerves. Patients with the LL form present a humoral response and lack of cellular 
response, with a predominance of CD8+ suppressor T cells and Th2 standard cytokines, such 
as IL-4, IL-5, IL-10 and IL-13, which inhibit the activation of macrophages. Here there is a 
proliferation of bacillus and presence of many lesions in the skin and peripheral nerves [5–7].
The disease can be classified into three forms: (i) Madrid (1953) classification, based on 
clinical and bacteriological criteria [8]; (ii) Classification of Ridley and Jopling (1966) that 
emphasizes clinical, bacteriological, immunological and histological aspects [9] and (iii) 
World Health Organization (WHO) (1982) operational classification with therapeutic pur-
pose, based on the bacilloscopic index, which is related to the clinical forms [10]. In 1988, this 
operational classification was updated and clinical criteria were also established, consider-
ing paucibacillary (PB) patients such as those with less than five cutaneous lesions and/or 
one affected nerve trunk and multibacillary (MB) such as those with more than six lesions 
and/or more than one affected nerve trunk. It is still considered MB when the bacilloscopy 
is positive, regardless the number of lesions [11]. The classifications adopted for clinical 
forms of leprosy such as Madrid, Ridley and Jopling and WHO are summarized and listed 
in Table 1.
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At present, it is known that there are several factors influencing the control and appearance of 
the disease, such as immune response, time of exposure to bacillus, virulence of the pathogen, 
environmental factors, genetic variation of the bacillus and, mainly, the immunogenetic vari-
ability of the host leading to susceptibility or resistance to leprosy per se [12–17], clinical forms 
[18–20] of the disease and leprosy reactions [21, 22] (Figure 1).
The selection of candidate genes in disease pathogenesis is usually based on two criteria: 
functional genes with a critical role in the pathogenesis of the disease and the location in the 
genomic region that may be involved in disease control; and yet a combination of the both. 
WHO Paucibacillary (PB) Multibacillary (MB)
MADRID Indetermined (I) Tuberculoid (T) Dimorph (D) Virchowian (V)
Ridley and Jopling TT BT BB BL LL
TT: tuberculoid-tuberculoid, BT: borderline tuberculoid, although presenting characteristics of the paucibacillar 
form, it has been operationally classified as multibacillary, BB: borderline borderline, BL: borderline lepromatous, 
LL: lepromatous-lepromatous.
Table 1. Correlation between the classifications of Madrid [8], Ridley and Jopling [9] and WHO [10, 11] adopted for 
leprosy.
Figure 1. Schematic representation of the clinical spectrum of leprosy suggesting the participation of different genes 
(HLA, MICA and KIR) in the control of the pathogenesis of the disease. Susceptibility or resistance to leprosy per se, 
clinical forms and leprosy reactions were showed. After exposure, most individuals are resistant to leprosy. Susceptible 
individuals may present the infection per se or develop one of the clinical forms and reactional types of leprosy, which 
are dependent on the host’s immune response pattern. MB: multibacillary, BB: borderline borderline, BL: borderline 
lepromatous, BT: borderline tuberculoid, LL: lepromatous leprosy, TT: tuberculoid leprosy; per se: leprosy independent 
of specific clinical manifestation. RR: type 1 or reversal reaction. ENL: type 2 reaction or erythema nodosum leprosum.
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These genes are generally those that participate in the immune response in leprosy, such as 
cytokine genes, HLA (human leukocyte antigen) genes, MICA (major histocompatibility com-
plex class I chain-related protein A) and KIR (killer cell immunoglobulin-like genes receptors), 
among others.
The two types of studies with molecular genetic markers are those of binding and association. 
The binding studies are related to the genetic mapping that allows the tracking of chromo-
somal regions linked to the disease. Gene-susceptibility/disease resistance studies are based 
on the comparison of the allelic frequencies of a genetic marker in populations (affected and 
unaffected individuals) [23].
Recently, a new approach to identify genes involved in human diseases is being carried out; it is 
the so-called genome-wide association study (GWAS). This is an association study of the entire 
genome in which many single nucleotide polymorphisms (SNPs) are tested in healthy controls 
and patients, allowing the analysis of hundreds or thousands of these polymorphisms at the 
same time. Genetic markers are considered to be associated with disease phenotypes when 
there is a significant difference in the frequencies observed between these two groups [24]. 
These works with genetic markers are performed aiming to contribute to the early diagnosis, 
prognosis, understanding of pathophysiology and improvement in the treatment of the disease.
Thus, the proposal of this chapter is to evidence the participation of some innate immune 
response genes, specifically, HLA, MIC and KIR genes, on overall leprosy and on evolution to 
the various clinic forms of disease.
2. Major histocompatibility complex
2.1. Introduction
The major histocompatibility complex (MHC) is composed of several genes, some of which are 
capable of encoding molecules that will display antigenic peptides on the cell surface for rec-
ognition by T cells. Other genes encode heat shock proteins, some cytokines and complement 
factors and approximately 40% of them have some function in the immune system [25, 26].
In relation to antigen presentation on the cell surface, the antigenic peptides originate from 
several sources, such as intracellular bacteria and viruses, products of cellular metabolism or 
proteins and lipids own or foreign to the organism [26].
In humans, a MHC sub region, called human leukocyte antigen (HLA), is located on the short 
arm of chromosome 6 and gives rise to HLA class I and II molecules. The HLA is polymor-
phic and each locus has many alleles contributing to human diversity as well as meeting the 
need for presentation of a wide range of antigens. The set of HLA alleles present on each 
chromosome is called haplotype, so all heterozygous individuals have two codominant HLA 
haplotypes [25, 27].
Understanding the mechanism of the presentation of antigens is of great importance for 
immunology, since it is able to explain events such as transplant rejection, autoimmune dis-
eases, tumor immunity and response to infection, such as leprosy [28].
Hansen's Disease - The Forgotten and Neglected Disease116
2.2. Structural characteristics
Each HLA molecule consists of a peptide-binding cleft, immunoglobulin (Ig)-like domains 
and transmembrane and cytoplasmic domains. Class I HLA has the α-chain encoded by MHC 
genes and the β2-microglobulin chain encoded by a non-MHC region. Class II HLA has both 
the α- and β-chain encoded in the MHC (Figure 2). The cleavage site is the site where the pep-
tides are established during their presentation to the T lymphocytes. In addition, cleft are the 
polymorphic residues, that the amino acids responsible for differentiating the HLA from each 
other, as well as making the presentations more antigenic specific. The Ig domains are non-
polymorphic and are responsible for binding between HLA and T cell: class I HLA molecules 
bind to CD8+ T cells and HLA class II molecules bind to the helper T cells CD4+ T cells [29, 30].
2.3. Nomenclature
The convention for the use of a four-digit code to name HLA alleles and distinguish them 
from the nomenclature given to coded proteins was introduced by the Nomenclature Report 
1987. Currently, an allele name can be composed of four, six or eight digits, depending on its 
sequence. The first two digits describe the allele family. The third and fourth digits refer to the 
way in which DNA sequences were discovered.
Alleles that are different in the initial four digits have differences in nucleotide substitutions, 
which alter in protein coding. The fifth and sixth digits are used to distinguish alleles that dif-
fer by the synonymous substitutions of nucleotides in the coded sequence. The seventh and 
eighth digits are used when the alleles differ by sequence polymorphisms in introns or in 5′ 
and 3′ untranslated regions.
Each HLA allele name has a unique number, corresponding to up to four sets of digits, sepa-
rated by a colon. The first two sets of digits are assigned to all alleles and the other two only 
for longer names and when needed (Figure 3) [31].
Figure 2. Structure of the class I and II MHC molecules.
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2.4. HLA classical
2.4.1. HLA class I
There are three classical loci belonging to MHC class I: HLA-A, HLA-B and HLA-C. They 
encode molecules that have the same name as their respective genes. HLA class I molecules 
are expressed in all nucleated cells and platelets, as these molecules present the antigenic pep-
tides for CD8+ T lymphocytes, which kill infected cells or with tumor antigens. The HLA-E, 
HLA-F and HLA-G loci also belong to HLA class I, but are considered non-classical (Figure 3) 
[32]. They are expressed at low levels when compared to classical HLA class I as well as do not 
have as many polymorphisms, and their functions in the immune system are limited [29, 30].
2.4.2. HLA class II
HLA class II molecules are expressed in dendritic cells, B lymphocytes, macrophages and 
other cell types, and present the antigenic peptides to the virulent CD4+ helper T lymphocytes, 
which recognize the antigens in the secondary lymphoid organs. Differentiated CD4+ helper T 
cells activate other cells, together with B lymphocytes, so that the extracellular microorganisms 
are eliminated. The three HLA class II loci are called HLA-DP, HLA-DQ and HLA-DR. The two 
chains of each molecule of class II are encoded by two different MHC genes. Thus, the extracel-
lular parts of α and β chains are subdivided into two segments, A1 and A2, or B1 and B2, both 
of which are polymorphic chains, that is, each of the DP, DQ and DR loci contain separate genes 
designated as A or B, which encode α and β chains, respectively, in each copy of chromosome 
6. Each individual has one HLA-DRA (DRA1), one to three DRB (DRB1 and DRB3, 4 and/or 5), 
one DQA (DQA1), one DQB (DQB1), one DPA (DPA1) and one DPB (DPB1) [25, 29, 30].
2.5. MICA and MICB genes
The human MHC class I chain-related genes (MICA and MICB) are located in the HLA class 
I region in chromosome 6, but are not part of the classical HLA (Figure 4). These genes show 
about 30% of homology to HLA class I, but the transcribed molecules do not present antigenic 
peptides on the cell surface. These genes are mainly transcribed into fibroblasts and epithelial 
cells. The MIC molecules bind to NKG2 receptors, activating NK cells and also modulate the 
function of CD8+ T cells. Studies have related associations of polymorphisms in MICA and 
MICB genes with several diseases (ankylosing spondylitis, psoriasis, dengue and tuberculo-
sis) [32–36], one of them being leprosy, which will be discussed in a next topic in this chapter.
Figure 3. Schematic example of the meanings for each code in the HLA nomenclature [31].
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2.6. HLA polymorphism
The immune system has the complex task of responding to different types of pathogens that come 
in contact with the human organism. Adaptation that ensures antigen protection and increased 
immune system efficiency can occur through life-long genetic recombination, such as antibody 
formation, or the different HLA molecules in the population. HLA molecules are responsible 
for presenting a fraction of the antigenic peptide (epitope) for T cells; however, the choice to 
determine which epitope will be presented according to the HLA genes and their alleles in each 
individual. Thus, the regions responsible for the antigenic presentation in the HLA molecules 
present high polymorphism rates. This means that with the advancement of diagnostic method-
ologies, the discovery of allelic variations of HLA has increased exponentially (Figure 5) [27, 29].
The evolutionary success in the amplification of the HLA repertoire may explain why it is 
difficult to associate a specific HLA phenotype with the susceptibility or protection against a 
particular disease, since the change of a single amino acid in the sequence of the HLA molecule 
can affect the adaptive immune response of the individual [32]. Despite this difficulty, studies 
have shown associations among several HLA and autoimmune and infectious diseases [27, 29].
Figure 4. Schematic map of the human MHC gene [32].
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2.7. Influence of HLA on leprosy
The role of HLA molecules in leprosy is to present epitopes of the bacillus to T lymphocytes. 
However, polymorphisms in HLA genes or incorrect presentation of the antigenic peptide 
may interfere or contribute to the success of the response of the host against the pathogen. In 
view of this, several studies have indicated genes associated with susceptibility or protection 
against leprosy in different populations (Tables 2 and 3).
Figure 5. Advances in the findings of allelic variations in HLA class I and II loci over the past 30 years. Class I HLA alleles 
are represented in green and class II HLA alleles in black [32].
Allele, 
haplotype
Population Population size Phenotype Association
A*02:06 Southern Indian 32 leprosy patients and 67 
healthy individuals
Leprosy per se Susceptibility [37]
A*02:06 Mumbai/Indian 103 leprosy patients and 101 
healthy individuals
Leprosy per se Susceptibility [14]
A*11 Brazilian 225 leprosy patients and 450 
healthy individuals
Leprosy per se Susceptibility [38]
A*11:02 Southern Indian 32 leprosy patients and 67 
healthy individuals
Leprosy per se Susceptibility [37]
A*11:02 Mumbai/Indian 103 leprosy patients and 101 
healthy individuals
Leprosy per se Susceptibility [14]
B*15 Brazilian 202 leprosy patients and 478 
healthy individuals
RR Susceptibility [22]
B*18:01 Mumbai/Indian 103 leprosy patients and 101 
healthy individuals
Leprosy per se Susceptibility [14]
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Allele, 
haplotype
Population Population size Phenotype Association
B*18:01 Southern Indian 32 leprosy patients and 67 
healthy individuals
Leprosy per se Susceptibility [37]
B*35 Brazilian 225 leprosy patients and 450 
healthy individuals
LL Protection [38]
B*38 Brazilian 225 leprosy patients and 450 
healthy individuals
Leprosy per se Susceptibility [38]
B*51:10 Southern Indian 32 leprosy patients and 67 
healthy individuals
Leprosy per se Susceptibility [37]
B*51:10 Mumbai/Indian 103 leprosy patients and 101 
healthy individuals
MB Susceptibility [14]
C*04 Brazilian 225 leprosy patients and 450 
healthy individuals
LL Protection [38]
C*04:07 Southern Indian 32 leprosy patients and 67 
healthy individuals
Leprosy per se Susceptibility [37]
C*04:07 Mumbai/Indian 103 leprosy patients and 101 
healthy individuals
MB Susceptibility [14]
C*04:11 Mumbai/Indian 103 leprosy patients and 101 
healthy individuals
MB Protection [14]
C*04:11 Southern Indian 32 leprosy patients and 67 
healthy individuals
Leprosy per se Protection [37]
C*05 Brazilian 202 leprosy patients and 478 
healthy individuals
B Protection [22]
C*07 Brazilian 225 leprosy patients and 450 
healthy individuals
Leprosy per se Susceptibility [38]
C*07:03 Southern Indian 32 leprosy patients and 67 
healthy individuals
Leprosy per se Susceptibility [37]
C*07:03 Mumbai/Indian 103 leprosy patients and 101 
healthy individuals
MB Susceptibility [14]
C*12 Brazilian 225 leprosy patients and 450 
healthy individuals
Leprosy per se Susceptibility [38]
C*16 Brazilian 225 leprosy patients and 450 
healthy individuals
Leprosy per se Protection [38]
C*15:05 Indian 364 leprosy patients and 371 
healthy individuals
Leprosy per se Susceptibility [15]
C*15:05 Vietnamese 198 families Leprosy per se Susceptibility [15]
C*15:05 Vietnamese 292 families Leprosy per se Susceptibility [15]
A*11-B*40 Mumbai/Indian 103 leprosy patients and 101 
healthy individuals
ML Susceptibility [14]
MB: multibacillary, PB: paucibacillary; B: borderline leprosy, BB: borderline borderline, BL: borderline lepromatous, 
BT: borderline tuberculoide, LL: lepromatous leprosy; TT: tuberculoid leprosy, per se: Leprosy independent of specific 
clinical manifestations, ENL: type 2 reactions or erythema nodosum leprosum, RR: Type I or reversal reaction.
Table 2. Associations between HLA class I and leprosy.
Immunogenetics of MHC and KIR in the Leprosy
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Allele, haplotype Population Population size Phenotype Association
DQA1*01:02 Indian 93 leprosy patients and 47 
healthy individuals
LL Susceptibility [39]
DQA1*01:03 Indian 93 leprosy patients and 47 
healthy individuals
LL Susceptibility [39]
DQA1*02:01 Indian 93 leprosy patients and 47 
healthy individuals
LL Susceptibility [39]
DQA1*03 Japanese 93 leprosy patients and 114 
healthy individuals
Leprosy per se Protection [40]
DQB1*02 Brazilian 202 leprosy patients and 478 
healthy individuals
B Protection [22]
DQB1*02:01 Brazilian 76 families (1166 individuals) TT Protection [41]
DQB1*02:01 Brazilian 76 families (1166 individuals) Leprosy per se Protection [41]
DQB1*02:01 Argentinean 89 leprosy patients and 112 
healthy individuals
LL Protection [42]
DQB1*02:02 Argentinean 89 leprosy patients and 112 
healthy individuals
LL Protection [42]
DQB1*02:03 Argentinean 89 leprosy patients and 112 
healthy individuals
LL Protection [42]
DQB1*04:01 Japanese 93 leprosy patients and 114 
healthy individuals
Leprosy per se Protection [40]
DQB1*05:01 Brazilian 76 families (1166 individuals) TT Susceptibility [41]
DQB1*05:01 Brazilian 76 families (1166 individuals) Leprosy per se Susceptibility [41]
DQB1*05:03 Indian 93 leprosy patients and 47 
healthy individuals
TT Protection [39]
DQB1*06:01 Indian 93 leprosy patients and 47 
healthy individuals
TT Susceptibility [39]
DQB1*06:01 Indian 93 leprosy patients and 47 
healthy individuals
LL Susceptibility [39]
DRB1*02 Japanese 79 leprosy patients and 50 
healthy individuals
BL/LL Susceptibility [43]
DRB1*04 Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Protection [44]
DRB1*04 Euro-Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Protection [44]
DRB1*04 Vietnam 194 single-case families Leprosy per se Protection [44]
DRB1*04 Argentinean 89 leprosy patients and 112 
healthy individuals
TT Protection [42]
DRB1*04:05 Japanese 93 leprosy patients and 114 
healthy individuals
Leprosy per se Protection [40]
DRB1*04:05 Taiwanese 65 leprosy patients and 190 
healthy individuals
MB Protection [45]
DRB1*07 Brazilian 76 families (1166 individuals) Leprosy per se Protection [41]
DRB1*07 Euro-Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Protection [44]
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Allele, haplotype Population Population size Phenotype Association
DRB1*07 Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Protection [44]
DRB1*07 Brazilian 202 leprosy patients and 478 
healthy individuals
B Protection [22]
DRB1*07:01 Indian 93 leprosy patients and 47 
healthy individuals
LL Susceptibility [39]
DRB1*08 Brazilian 169 leprosy patients and 217 
healthy individuals
LL Susceptibility [46]
DRB1*08:08 Argentinean 71 leprosy patients and 81 
healthy individuals
Leprosy per se Protection [47]
DRB1*09 Southern Indian 230 leprosy-affected sib-pair TT Protection [48]
DRB1*09 Chinese 305 leprosy patients and 527 
healthy individuals
Leprosy per se Protection [49]
DRB1*10 Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Susceptibility [44]
DRB1*10 Afro-Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Susceptibility [44]
DRB1*10 Vietnam 194 single-case families Leprosy per se Susceptibility [44]
DRB1*11 Brazilian 70 leprosy patients and 77 
healthy individuals
LL Protection [50]
DRB1*11:03 Argentinean 71 leprosy patients and 81 
healthy individuals
Leprosy per se Protection [47]
DRB1*12 Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Protection [44]
DRB1*12 Japanese 79 leprosy patients and 50 
healthy individuals
Leprosy per se Protection [43]
DRB1*14 Brazilian 85 leprosy patients and 85 
healthy individuals
TT Susceptibility [20]
DRB1*14:01 Argentinean 71 leprosy patients and 81 
healthy individuals
Leprosy per se Susceptibility [47]
DRB1*14:06 Argentinean 71 leprosy patients and 81 
healthy individuals
Leprosy per se Susceptibility [47]
DRB1*15 Afro-Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Susceptibility [44]
DRB1*15 Brazilian 578 leprosy patients and 691 
healthy individuals
Leprosy per se Susceptibility [44]
DRB1*15 Chinese 305 leprosy patients and 527 
healthy individuals
Leprosy per se Susceptibility [49]
DRB1*15 Indian 93 leprosy patients and 47 
healthy individuals
TT Susceptibility [39]
DRB1*15 Indian 93 leprosy patients and 47 
healthy individuals
LL Susceptibility [39]
DRB1*15 Indian 54 leprosy patients and 44 
healthy individuals
TT Susceptibility [51]
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3. MIC genes
The findings of new immune response genes are occurring in order to clarify their possi-
ble participation in the occurrence or severity of a disease. Among them, we can highlight 
MIC (MHC class I chain-related genes) that were discovered during a search for new coding 
sequences, located near the HLA-B gene [55].
MIC constitutes a second lineage of non-classical MHC class I genes and correspond to the 
MICA, MICB, MICC, MICD, MICE, MICF and MICG loci (Figure 6). MICA genes are located on 
the short arm of chromosome 6 (6p21.3), about 46.5 kb from HLA-B toward the centromere. 
Only MICA and MICB are expressed in proteins that belong to the immunoglobulin super-
family (IgSF) [56–58].
Like classical HLA genes, MICA also shows a high polymorphism in humans, whereas MICB 
appears to be less polymorphic, although it has been little explored. Since the discovery and 
characterization of NKG2D as its corresponding receptor in NK cells and in subsets of T 
cells, these genes have received increasing attention in the context of organs and stem cell 
Allele, haplotype Population Population size Phenotype Association
DRB1*15:01 North Indian 113 leprosy patients and 111 
healthy individuals
BL/LL Susceptibility [52]
DRB1*15:01 Indian 93 leprosy patients and 47 
healthy individuals
LL Susceptibility [39]
DRB1*15:02 Southern Indian 230 leprosy-affected sib-pair TT Susceptibility [48]
DRB1*15:02 Indian 93 leprosy patients and 47 
healthy individuals
TT Susceptibility [39]
DRB1*15:02 Indian 85 leprosy patients and 104 
healthy individuals
TT Susceptibility [53]
DRB1*15:02 Asian Indian 27 leprosy patients and 19 
healthy individuals
TT Susceptibility [54]
DRB1*16 Brazilian 85 leprosy patients and 85 
healthy individuals
LL Susceptibility [20]
DRB1*16:01 Brazilian 169 leprosy patients and 217 
healthy individuals
BL Susceptibility [46]
DRB5*01:01 Indian 93 leprosy patients and 47 
healthy individuals
LL Susceptibility [39]
DRB1*15:01-
DRB5*01:01-
DQA1*01:02-
DQB1*05:02
Indian 85 leprosy patients and 104 
healthy individuals
TT Protection [53]
MB: multibacillary, PB: paucibacillary; B: borderline leprosy, BB: borderline borderline, BL: borderline lepromatous, 
BT: borderline tuberculoide, LL: lepromatous leprosy; TT: tuberculoid leprosy, per se: Leprosy independent of specific 
clinical manifestations, ENL: type 2 reactions or erythema nodosum leprosum, RR: type 1 or reversal reaction.
Table 3. Associations between HLA class II and leprosy.
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transplantation. MICA and MICB encode glycoproteins, which are stress induced and can 
be recognized by receptors such as NKG2D (C-type lectin-like activating immunoreceptor). 
They are capable of inducing immune responses involving Tγδ cells and NK cells, indepen-
dently of the processing of conventional class I MHC antigens [57, 59, 60].
3.1. Structure of the MIC molecule
MICA molecules are codominantly expressed and are polypeptides of 383–389 amino acids 
with a size of 43 kDa in length [56, 57] and the MICB molecules are also polypeptides with 
a similarity of 83% amino acids with MICA. The structure of the MICA molecule is similar 
to HLA class I antigens, with three extracellular domains (α1, α2 and α3), a transmembrane 
domain and a cytoplasmic tail. MICA molecules have an extremely flexible rod connected to 
the platform formed by the α1/α2 domains and the α3 domain. Four α-helices are arranged 
under eight pleated β-strands forming a reduced slit that it would not be possible to attach a 
peptide composed of more than three or four amino acid residues (Figure 7) [61].
Figure 6. Genes and pseudogenes of the MIC family on region class I of the human MHC. Functional genes are 
represented in blue and the pseudogenes in yellow.
Figure 7. The structure of the MICA. Exon 2 encodes a leader peptide, exons 2–4 encode three extracellular domains, 
exon 5 a transmembrane domain and exon 6 a cytoplasmic tail [61].
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In exon 5, there is a short tandem repeat sequence (STR) at position 304 consisting of GCT 
nucleotide breaks, which encode the amino acid alanine in the transmembrane region (TM). 
STR is absent in MICB. Based on the number of GCT, the alleles are named as A4, A5, A5.1, 
A6, A7, A8, A9 and A10. A5.1 differs from A5 by the insertion of a guanine nucleotide in the 
GCT (GGCT) [62], leading to a change in the reading matrix causing a terminus premature 
codon within the exon that encodes the transmembrane domain [33, 63, 64]. Thus, A5.1 is a 
35–40 kDa truncated glycoprotein that eventually reaches the cell surface, but not at its physi-
ological site. This is another characteristic of the MICA polymorphism: several alleles have 
identical extracellular domains but differ in the TM region. The identification of the polymor-
phism in the TM region is essential to avoid ambiguities [65].
The expression of the MICA gene was recognized in gastrointestinal and thymic epithelial 
cells in isolated endothelial cells, fibroblasts and keratinocytes. MICA molecules are ligands 
of the NKG2D receptors and Tγδ cell receptors (TCRγδ). The recognition of the MICA mol-
ecules by Tγδ Vδ1 cells through the interaction with the α1 and α2 domains was confirmed 
later in another study [66].
Tγδ cells constitute a small population of T cells expressing antigenic receptor proteins that 
resemble those of CD4+ and CD8+ T cells, but are not identical. Tγδ cells recognize many dif-
ferent types of antigens, including some proteins and lipids, as well as small phosphorylated 
molecules and alkyl amines. These antigens are not presented by MHC molecules [25]. It is 
not known whether there is a need for a particular cell type or distinct antigen presentation 
system for the presentation of antigens to these cells. MICA molecules are also recognized by 
their NKG2D receptors present on the surfaces of NK cells, associated with DAP10 molecule. 
This NKG2D-MICA complex activates phosphorylation of the tyrosine residues of the DAP10 
molecule, triggering a cascade of cell signaling that enhances the cytotoxicity of NK cells. This 
complex also enhances the production of IFN-γ by NK cells, participating as a co-stimulator 
factor in the immune response against Mycobacterium [67].
Therefore, MICA is a stress-induced MHC class I molecule that binds to NKG2D receptors, 
primarily NK cells, stimulating NK cells, T CD8+ cells and some Tγδ cells [68]. Previous stud-
ies have suggested that HLA-B loci alleles were associated with some diseases caused by 
pathogens and, as there is strong linkage disequilibrium between the two genes due to the 
proximity of MICA, this could indirectly contribute to this response.
3.2. Association of MICA and MICB genes with leprosy
Some infectious and noninfectious diseases such Behçet’s disease, ankylosing spondylitis, 
Reiter’s syndrome, Kawasaki disease, psoriasis vulgaris and Chagas disease have been associ-
ated to MICA genes. These studies suggest that allelic variants of MICA may be directly related to 
NKG2D receptor binding of Tγδ and NK cells affecting the effects of cells activation [35, 69–74].
In the first study of association between the MICA gene and leprosy, the MICA*A5 allele 
was found associated with protection against MB form in Chinese patients [19]. In India, 
the MICA*5A5.1, MICB*CA16 and MICB*CA19 alleles were associated with susceptibility to 
leprosy per se and MICB*CA21 allele with protection [48]. Recently, in a study in Brazil, the 
MICA*010 and MICA*027 alleles were associated with protection against the MB form and 
MICA*027 was associated with protection to leprosy per se [16].
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4. Killer cell immunoglobulin-like receptors (KIRs)
4.1. Natural killer cells
Natural killer (NK) cells make up about 10–15% of the lymphocytes in human peripheral 
blood, with an important participation on the innate immune response. In addition, they are 
sources of type I cytokines, IFN-γ, as well as TNF-α, granulocyte macrophage colony-stim-
ulating factor (GM-CSF) and other cytokines and chemokines [75]. In their original lineage, 
repertoire of receptors and effector functions, the NK cells appear to be a transitional cell 
type, which would be a bridge between the innate and adaptive immune system. The name 
is derived from two aspects: (i) NK cells are able to mediate their effector function (lysis of 
target cells) spontaneously in the absence of prior sensitization and are then called “killer” 
and “natural” and (ii) another aspect is that they perform their function with a very limited 
repertoire of receptors encoded in progenitor lines that do not undergo somatic recombina-
tion. The absence of previous sensitization and the absence of gene rearrangement for the 
formation of receptors for target cells indicate that NK cells are part of the innate immune 
system [76]. The major surface markers associated with NK cells are CD16 and CD56, while 
the T cell receptor (TCR) is absent [77].
The function of NK cells is to remove abnormal cells from the host, as infected cells or tumor 
cells, by exocytosis of lytic proteins (perforin/granzyme pathway) and by FasL or TRAIL 
(factor-apoptosis inducing linker of tumor necrosis) expression. Chemokines secreted by NK 
cells, such as IFN-γ and TNF-α, can mediate cytotoxic effects, activate dendritic and T cells, 
and influence the individual’s immune response [78].
NK cells perform their task using two sets of receptors: activators and inhibitors present on 
their surface that interact with binding molecules on the surface of the target cell. The balance 
of these interactions determines whether or not the NK cell will be activated [9]. The major 
activation receptors expressed on NK cells include FcγRIIIA (CD16), DNAM-1 (CD226), 
NKG2C (KLRC2: killer cell lectin-like C2 receptor), NKG2E (KLRC3: killer cell lectin-like C3 
receptor), NKG2D (KLRK1: killer cell lectin-like receptor K1), KIR-activating forms (KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5 and KIR3DS1), natural cytotoxicity receptors (NCRs) 
called NKp30 (natural cytotoxicity triggering receptor 3), NKp46 (NCR1: natural cytotoxicity 
triggering receptor 1), NKp65 (KLRF2: killer cell lectin-like F2 receptor) and NKp80 (KLRF1: 
killer cell lectin-like F1 receptor). The inhibitory receptors are KIR2DL1, KIR2DL2, KIR2DL3, 
KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3, NKG2A (KLRC1: killer cell lectin-like C1 recep-
tor), LILRB1 (leukocyte immunoglobulin-like B1 receptor), KLRG1 (NKR2B4: natural killer 
cell receptor 2B4), NKp44 (NCR2: natural cytotoxicity triggering receptor 2) and KIR2DL4 
(NKR2B4: natural killer cell receptor 2B4) [75].
4.2. KIR molecules
KIRs are members of a group of regulatory molecules found on the surface of NK cells and 
T cell subpopulations. They were first identified for their ability to confer some specificity 
in cytolysis mediated by NK cells [79, 80]. This specificity occurs through the interaction of 
isotypes of KIR with HLA class I molecules, protecting unaltered cells from the destruction 
caused by NK cells. Different types of KIRs can be expressed on the surface of NK cells, 
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which may be activators or inhibitors [79], with a combinatorial selection of receptors to be 
expressed by the cell.
Thus, in an individual, NK cells can randomly express a different set of activating and inhibi-
tory receptors, and not all NK cells in an individual have the same receptors. This differential 
expression between NK cells and certain KIR/HLA interactions may contribute to heterogene-
ity in NK cell activation levels, observed both among different individuals and among distinct 
NK cell subpopulations of the same individual [81].
NK cells become responsible for tolerance when their inhibitory KIRs identify class I HLA 
surface molecules as self-antigens, and trigger inhibitory signaling through the tyrosine kinase 
phosphorylation of intracytoplasmic inhibition motifs based on tyrosine immunosorbent 
(ITIM) [82]. Even with the presence of activating receptors, the inhibitory signal is translated 
into tolerance, absence of cytotoxicity and cytokine production by NK cells when the target 
cell is normal. When the cell is infected with a virus or transformed into a tumor cell, this toler-
ance environment is altered, especially by the low or no expression of HLA class I molecules, 
which is known as part of the escape mechanism of tumor cells to the adaptive immunity [83].
NK cells are activated to produce cytotoxicity and cytokines, precisely due to the escape mech-
anism of altered ITIM cells; but alternatively there are positively charged transmembrane 
residues, which facilitate the physical association with DAP12 accessory proteins, releasing 
the activating signal via immunoreceptor tyrosine-based activation motifs (ITAM) [75].
4.3. KIR genes
The KIR genes are located on chromosome 19 (19q13.4) in a 1 Mb gene complex called the 
leukocyte receptor complex (LRC) which is shown in Figure 8. There are several gene families 
in the LRC region, among them leukocyte Ig-like receptors (LILRs); Ig-like transcripts (ILTs); 
killer cell Ig-like receptors (KIRs); platelet collagen receptor glycoprotein VI (GPVI); Fc IgA 
receptors, FcGammaR; natural cytotoxicity triggering receptor 1 (NRC1); leukocyte-associ-
ated Ig-like receptors (LAIRs); sialic acid-binding immunoglobulin-like lectins (SIGLECs); 
members of the CD66 family, such as the carcinoembryonic antigen (CEA) genes and the 
genes encoding the transmembrane adapter molecules DAP10 and DAP12 [84, 85].
The KIR gene family has 15 genes (KIR2DL1, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, 
KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2D5, KIR3DL1, KIR3DL2, KIR3DL3 and KIR3DS1) 
and 2 pseudogenes (KIR2DP1 and KIR3DP1). They are divided into two functional groups: 
inhibitors that prevent lysis of the target cell and the activators that cause lysis of the target 
cell. The inhibitory group has eight genes that are KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL5A, 
KIR2DL5B, KIR3DL1, KIR3DL2 and KIR3DL3; the activator group has genes such as KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5 and KIR3DS1; while KIR2DL4 may be an activator 
or inhibitor. Between them, there are four KIR genes that are called structural (framework) 
genes, since they are present in almost all individuals: KIR3DL3, KIR3DP1, KIR2DL4 and 
KIR3DL2 [85, 86].
4.4. Structure and nomenclature of KIR
The naming of KIR genes is responsibility of the HUGO Genome Nomenclature Committee 
(HGNC) [87]. The designation of the KIR gene system considers the structure of the KIR protein. 
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They are classified based on two characteristics: number of extracellular Ig domains (2D or 3D) 
and characteristics of the cytoplasmic tail of the KIR protein, being S for short tail and L for long 
tail [88]. KIR3D is formed by the domains D0, D1 and D2, while KIR2DL1, KIR2DL2, KIR2DL3 
and all KIR2DS have the D1 and D2 (Type I) domains; and KIR2DL4 and KIR2DL5 have the 
domains D0 and D2 (Type II) [89]. The long cytoplasmic tail (L) is associated with ITIM motifs 
that release a signal of inhibition to the cell. This signal of inhibition is due to the phosphoryla-
tion of a tyrosine residue that promotes the recruitment of (SHP-1 and SHP-2), which promote 
the dephosphorylation of protein substrates of tyrosine kinases related to the activation of NK 
cells. On the other hand, short tail (S) activation receptors have ITAM motifs in their trans-
membrane domain that associate with the adapter molecule DAP-12. The interaction of these 
receptors with their ligands results in the recruitment of SyK and ZAP-70 tyrosine kinases by 
ITAMs, resulting in the reorganization of the cytoskeleton to release granules and also in the 
transcription of cytokine and chemokine genes [90]. The structural characteristics of KIR that 
define their nomenclature are represented in Figure 9.
The KIR pseudogenes are identified by the letter “P” just after the digit corresponding to the 
domain type, as in the pseudogenes: KIR2DP and KIR3DP.
KIR genes follow a basic organization structure with 4–9 exons. Exons 1 and 2 encode the protein 
leader sequence; exons 3, 4 and 5 encode extracellular domains (D0, D1 and D2, respectively); 
Figure 8. Diagram showing the cluster genes of the extended leukocyte receptor complex located (LRC) on chromosome 
19 with highlight to KIR A haplotype at position 19q13.4 (in red). Among the molecules encoded by the extended LRC 
set of genes are the DAP adaptor proteins, CD66 antigens, SIGLEC, FcGRT, LILR, LAIR, FcAlphaR and NCR1 receptors. 
Within the KIR A haplotype are the framework genes (blue boxes), pseudogenes (purple box), inhibitory KIR (red 
boxes) and activating KIR genes (green box). KIR2DL4 can be an inhibitory or an activating gene and KIR3DP1 is also 
considered as framework gene [86].
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exon 6 encodes the tail, which lies between the extracellular domain and the membrane; exon 7, 
the transmembrane portion; and exons 8 and 9 encode the cytoplasmic tail [91].
4.5. KIR haplotypes
The KIR genes in the LRC form haplotypes on the same chromosome passed in blocks from 
generation to generation. There are two groups of KIR haplotypes: A and B, differentiated 
mainly by the number of activator KIR genes [92].
The A haplotype has seven KIR genes, predominantly the genes that encode the inhibitor 
receptors, such as KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2 and KIR3DL3, with only 
Figure 9. Domain structure of the KIR molecules. The structural characteristics of two and three Ig-like domain KIR 
proteins are shown. The association of activating KIR to adaptor molecules is shown in green, whereas the ITIM 
of inhibitory KIR are shown as red boxes. KIR2DL4 contains signature sequences of both activating and inhibitory 
receptors [86].
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one activator gene, KIR2DS4. The B haplotype has a greater diversity of genes: KIR2DL5, 
KIR2DL2, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1, with the activation signals 
predominating. A and B haplotypes have the frameworks genes [86, 93].
The KIR Nomenclature Committee considered that the distinction between A and B haplo-
types is useful in biological and clinical terms, and thus developed a consistent and logical set 
of criteria to distinguish them. Therefore, a haplotype can, for example, be called KH-001A or 
KH-022B [86]. The haplotypic diversity of KIR genes varies in different populations, suggest-
ing that there may be variable effects of the receptors on several diseases, offering protection 
against one particular pathology or predisposition to the other.
4.6. KIR ligands
NK cells perform the recognition of foreign cells in the body through the interaction of KIRs 
on own cell surface with ligands on target cells surface: classical class I HLA-specific mol-
ecules (HLA-A, HLA-B and HLA-C) and non-classical (HLA-E and HLA-G) [94]. The activity 
of NK cells requires the interaction between a given class I HLA antigen expressed on the 
surface of the cells and a specific KIR, inhibitor or activator.
HLA-C molecules are the major ligands of KIR and can be distinguished in two groups of 
ligands (C1 and C2). All HLA-C carry a valine (V) at position 76 and a dimorphism in the 
position 80, which may be asparagine (N) or lysine (K). The alleles that have asparagine at 
position 80 are called C1 group (codifying by C*01, C*03, C*07, C*08, C*12, C*13, C*14, C*16:01, 
C*16:03 and C*16:04) and are the ligands of KIR2DL2/KIR2DL3 and KIR2DS2. On the other 
hand, the molecules that possess lysine at position 80 (K80) belong to the C2 group (codify-
ing by C*02, C*04, C*05, C*06, C*15, C*16:02, C*17 and C*18 genes) and bind to KIR2DL1 and 
KIR2DS1 [95].
Some HLA-B molecules express Bw4 epitopes that are also present in some HLA-A mol-
ecules encoded by HLA-A*09, HLA-A*23, HLA-A*24, HLA-A*24:03, HLA-A*25 and HLA-
A*32. The KIR3DL1 and the KIR3DS1 interact with HLA-Bw4, which differs from Bw6 due 
to a polymorphism at position 77 and 80. Bw4 molecules may have multiple amino acids at 
the position 77, either asparagine or aspartic acid or serine, and a dimorphism at the posi-
tion 80, which may be isoleucine or threonine. The allotypes containing Bw4 with Isoleucine 
(Bw4-80I) generally exhibit strong inhibition, while Bw4 alleles with Threonine (Bw4-80 T), 
such as those encoded by HLA-B*13, HLA-B*27, HLA-B*37:01 and HLA-B*44, appear to be 
better ligands for certain KIR3DL1 subtypes. Other KIRs have less defined specificities, such 
as KIR3DL2, which recognizes HLA-A variants (A3 and A11), KIR2DL4 recognizing HLA-G 
and KIR2DS4 recognizing C*04. The ligands for KIR2DL5, KIR2DS3, KIR2DS5, KIR3DS1 and 
KIR3DL3 have not been identified to date [95, 96].
Although KIR activators exhibit a ligand recognition structure very similar to inhibitory 
receptors, as in the 2DL1/2DS1-C2 group pair and the triad of 2DL2/2DL3/2DS2-C1 group, 
the binding affinity of the activating variants is strongly reduced in comparison to the inhibi-
tory variants. Therefore, when there are binding of inhibitory and activating receptors at the 
same time, it is believed that the inhibitory signal prevails [96].
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4.7. Influence of KIR genes and ligands on leprosy
It is known that the interaction of KIRs and their HLA ligands can result in activation or 
inhibition of NK cells and the occurrence of different immunological and clinical responses to 
various types of diseases, such as infectious diseases (AIDS, malaria, tuberculosis, Chagas dis-
ease, dengue fever and leprosy) [97–101], autoimmune and inflammatory diseases (psoriasis, 
rheumatoid vasculitis and Crohn’s disease) [102–104] in different populations and ethnicities.
The pioneering studies of KIR genes in leprosy were carried out in Brazil. The first study was 
performed in the southern region of Brazil, where the KIR2DL1 inhibitor gene with its C2 group 
ligand was shown to be protective for BB and its homozygous ligand (KIR2DL1-C2/C2) was asso-
ciated with the clinical form TT. Another inhibitory gene and its ligands (KIR3DL2-A*03/A*11) 
were associated with susceptibility to borderline leprosy. The activating genes KIR2DS2 and 
KIR2DS3 were shown to be a risk factor for TT form, compared to the more widespread form 
LL. Thus, TT patients with both activating genes (KIR2DS2 and KIR2DS3) may develop better 
activation of NK cells and a competent cellular immune response with a more localized mani-
festation of the disease. The inhibitory KIR2DL3-C1 and KIR2DL3-C1/C1 were associated to 
protection against TT form, when compared to the control group and other clinical forms [105].
The second study of KIR genes with leprosy was performed in a hyperendemic region of 
Brazil, and the KIR2DL1 inhibitory gene was a protective factor for leprosy per se and its 
BB form. The frequency of the homozygous KIR2DL2 gene in the presence of the C1 group 
(KIR2DL2/KIR2DL2-C1) was higher in leprosy patients per se and in clinical forms TT and LL, 
when compared to the control group. The KIR2DL2/KIR2DL3 haplotype with its homozygous 
C1 ligand (C1/C1) was associated with protection for leprosy per se and TT and LL forms [17].
The inhibitory effect of KIR2DL2/2DL2-C1 may contribute to the development of leprosy, 
mainly to a worse prognosis in M. leprae infections. The activating KIR2DS2 gene with its C1 
ligand was a risk factor for leprosy per se and the clinical form TT. In this same study, it was 
observed that higher frequency of inhibitory genes may favor the susceptibility of the devel-
opment of the disease [17]. Thus, this study confirmed the influence of KIR genes and their 
HLA ligands on the immunopathology of leprosy.
Activating and inhibitory KIR genes in the presence of their HLA ligands may have an impact 
on the development of leprosy and its clinical forms. The balance between these genes may 
interfere with the progression of the disease to a more localized (TT) or disseminated (LL), or 
to maintain an intermediate pattern between the two poles (BB), thus highlighting the role of 
NK cells and the production of cytokines.
5. Conclusions
This chapter outlined the contribution of the innate and adaptive immune genes to leprosy 
pathogenesis, highlighting the HLA, KIR and MIC polymorphism genes contribution for clini-
cal forms and reactions of leprosy. Immune responses against the M. leprae vary considerably 
between populations, which can be partly attributed to the genetic variation of the immune 
response to ensure the survival of populations. HLA and non-HLA genes should act together 
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affecting the susceptibility to leprosy, resulting in different clinical manifestations or reac-
tions. Hence, for a complete understanding of the genetic mechanisms of leprosy suscepti-
bility, it will be necessary to join efforts to present a pattern of genes that would in fact be 
important to predict a clinical form or more severe reaction of the disease.
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